Surgical Management of HCC by Lochan, R et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 13
Surgical Management of HCC
R Lochan, HL Reeves and DM Manas
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55743
1. Introduction
Hepatocellular cancer (HCC) accounts for approximately 80% of all primary liver cancers. It is
the fifth most common cancer worldwide and is the third leading cause of cancer related deaths
across the world, with a case fatality rate of 0.93 making it one of the most lethal malignancies [1].
In the majority of cases, HCC develops in the setting of cirrhosis and treatment with curative
intent is only possible in a minority of cases. The incidence of HCC continues to rise world‐
wide, due in part to the rising number of people who have hepatitis C virus (HCV) infection,
infection with hepatitis B virus (HBV), (but not to the same degree as HCV) and non-alcoholic
fatty liver disease (NAFLD). NAFLD is now the most rapidly rising cause of cirrhosis in the
developed world. The outcome from this disease is poor, with a median survival estimated at
around 1-year following diagnosis [2]. In keeping with global trends, the incidence and conse‐
quent mortality from HCC in the United Kingdom is also increasing, despite greater aware‐
ness for the need for surveillance in patients with cirrhosis, and improvements in and access to
imaging. This is thought to be secondary to the persistence of alcohol induced liver disease as a
significant cause of CLDs [3], the growing incidence of non-alcoholic fatty liver disease (NAFLD)
in the UK, immigration to the UK from HBV-endemic countries and the clinical impact of HCV
infected individuals, infected before HCV screening of blood products (in the 1990’s).
HCC is unique amongst solid cancers in that the outcome from it depends not only on the
performance status of the patient and biological behaviour of the tumour, but also on the
degree of liver dysfunction. The current treatment options are surgical (liver resection [LR],
liver transplant [LT]), ablative (radiofrequency or microwave ablation [RFA/MCT]), non-
surgical (trans-arterial chemo-embolisation, selective internal radiation therapy [yttrium90
spheres]) and medical - in particular the use of the targeted kinase inhibitor, Sorafenib. The
only curative treatments are the surgical modalities (LR or LT). However these treatments are
not suitable for the majority of patients but can achieve the best outcome in carefully selected
patients with early tumours or very early tumours. Sometimes LR and LT are complimentary,
particularly when LR is considered as a bridge to transplantation. When the liver parenchyma
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is normal [5% of the cases in Western countries, and for about 40% in Asia] the treatment of
choice is a liver resection (LR) [4]. However most patients also have underlying chronic liver
disease and for this group of patients, LT is the treatment of choice as it treats not only the
tumour but the underlying chronic liver disease which induces tumourigenesis in the first
place. However the relative scarcity of donor organs available for transplantation (NHSBT)
and the improved outcomes of LR amongst those with chronic liver disease (CLD) have led to
an increased interest in LR for HCC.
For patients with early HCC and CLD who have well-preserved liver function (the vast
majority of patients), establishing the best treatment is difficult as there are no well designed
randomized controlled trials to guide management. Proposed treatment modalities for
individual patients need to take into account not only tumour factors (stage of tumour) but
also the degree of underlying chronic liver disease and patient factors (performance status).
The Barcelona Clinic Liver Cancer (BCLC) algorithm which incorporates these variables into
a decision making process to help choose a specific management option has been found most
useful in clinical practice [5].
2. Liver resection as treatment for HCC
2.1. Selection criteria of patients with HCC for Liver Resection (LR)
Clearly extra-hepatic and or distant spread is a contra-indication for LR. This occurs in 60-80%
of cases. There is a significant geographical variation in the proportion of patients undergoing
surgery with curative intent, varying from 20% in East Asia, through 25-40% in Europe, to
50-70% in Japan. Superior outcomes being related to the implementation of effective screening
programs [6].
In addition to the patients overall performance status, the following specific factors need to be
considered
1. The Tumour:
a. Stage
b. Size
2. The Liver parenchyma
a. Underlying chronic liver disease (CLD) and portal hypertension (PHT)
b. Quality and volume of the “future functional liver remnant”(FLR)
3. Tumour specific factors
3.1. Staging of HCC
Resection of any cancer is based on pre-operative staging to a large extent. In addition, a proper
cancer staging is useful for evaluating prognosis of cancer patients, for tailoring therapy and
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monitoring therapeutic response. Generally prognosis in solid cancers is solely related to stage.
However HCC is unique in that cirrhosis underlies the cancer and thus outcome is related too
not only tumor but also to the extent of liver parenchymal damage. Therefore any staging for
cirrhotic patients with HCC should take into consideration the severity of the liver disease and
the extent of the tumour. Numerous staging systems have been described (at least 8), although
none has been universally accepted. The variables used in each classification as well as the
populations in which they were derived are different. Only 3 – BCLC, CLIP and JIS have been
validated in different cohorts of patients [7]- [12]. The BCLC and Cancer of the Liver Italian
Program (CLIP) staging systems have been the most popular in Europe and the USA, and the
Japan Integrated Staging Score (JIS) in Japan.
The Okuda staging system includes tumour size, serum albumin, bilirubin and ascites [13].
The Child’s classification does not discriminate enough for Child’s A or B patients in whom
resection is being considered in order to prevent postoperative liver de-compensation. The
Cancer of the Liver Italian Program (CLIP) is based on the Child–Pugh class, tumour progres‐
sion, alpha-fetoprotein (AFP) and presence of portal venous thrombosis. CLIP is the most
accurate for prognosis [12] especially in patients with advanced HCC and those undergoing
loco-regional therapy [14]. Specifically, a CLIP score of less than 2 predicts better response and
longer survival [15]. The BCLC system assesses tumour stage, liver function, physical status
and cancer-related symptoms, linking these in a widely used treatment algorithm [16], [17]
[18]. The BCLC is the only system that links prognosis with treatment recommendations, and
is therefore selected in several major trials of HCC therapy.
Conventional methods like TNM (e.g. TNM) exclude the functional status of the liver, which
is an important consideration in these patients. However in patients with intermediate or
advanced HCC who undergo surgery the AJCC/UICC system is useful [19]– the parameters
include tumour size and number, vascular invasion (micro/macro) and degree of fibrosis Ishak
grade. The 7th edition [20] has further refined prognostication for the intermediate/advanced
stages of the disease and this continues to be where this staging system is useful but does not
really improve discrimination for early HCC.
Other tumour factors known to impact on outcomes after LR include size of lesion, satellite
nodules, serum AFP, margin status, vascular involvement and UICC stage 3 or 4 disease. These
factors therefore need to be considered carefully prior to consideration of hepatectomy for HCC.
Size of lesion: It is unsurprising that the size of the lesion impacts on outcome after LR. Larger
lesions indicating increased tumour load with increased risk of vascular invasion, need
increased liver mass to be resected and therefore contribute to a lesser future functional liver
remanant (FLR) on a background of underlying CLD. Smaller tumour size is a well-accepted
as an important independent prognostic indicator for overall survival [22]- [25] but not disease-
free survival. From a multi-institutional cohort of 557 patients, tumour size if less than 5 cm
resulted in 43% 5-year survival compared to 32% for larger tumours. HR (95% CI) for recurrent
disease and death if lesion more than 5 cm was 1.4 (1.1 – 1.9) [26]. In a series of 12,118 patients
from Japan, size less than 2 cm was an independent predictor of survival compared to larger
tumours (2 cm, 2-5 cm, 5-10 cm and more than 10 cm; 5 year survival 66%, 53%, 37% and 31%
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Okuda staging 
 Negative Positive Stage 
Tumour size <50% of Liver >50% of Liver I: no positive factors 
Ascites Absent Present II: 1-2 positive factors 
Bilirubin <51 mmol/L >51mmol/L III: 3-4 positive factors 
Serum Albumin >3g/dL <3g/dL  
Child-Turcotte-Pugh classification 
 1point 2 points 3 points Class 
Encephalopathy None Grade 1-2 Grade 3-4 A 5-6 points 
Bilirubin <2 2-3 >3 B 7-9 points 
PT/INR <1.7 1.7-2 >2 C 10-15 points 
Ascites None Controlled on Rx Refractory
Albumin (g/L)    
CLIP – Cancer of the Liver Italian Program 
Points CTP Tumour 
morphology 
AFP PV 
thrombosis 
0 A Uninodular 
≤50% of Liver 
 No 
1 B Multinodular 
≤50% of Liver 
 Yes 
2 C Massive>50% of 
Liver 
  
BCLC – Barcelona caner of Liver Clinic staging 
Stage Performance 
status 
Tumour stage PHT Bilirubin Classification 
A1 0 Single No Normal Very early 
A2 0 Single Yes Normal Early 
A3 0 Single  Yes Raised  
A4 0 3 tumours, <3 cm each Yes Raised  
B 0   Intermediate 
C 1-2 Vascular invasion Advanced 
D 3-4 Any tumour Terminal 
AJCC TNM 7th 
edition 
    
Stage T N M 
I T1 solitary tumour, no vascular invasion N0  M0 
II T2 Solitary tumor with vascular invasion 
or multiple tumors, none > 5 cm 
N0 M0 
IIIA T3a Multiple tumors > 5 cm N0 M0 
IIIB T3b Single tumor or multiple tumors of 
any size involving a major branch of the 
portal or hepatic vein 
N0 M0 
IIIC T4 Tumor(s) with direct invasion of 
adjacent organs other than gallbladder or 
with visceral peritoneum  
N0 M0 
IVA Any T N1 M0 
IVB Any T Any N M1 
Table 1. Table of various staging systems [21]
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respectively). In this study on multivariate analysis, tumour size less than 2 cm resulted in a
significantly better overall survival. Therefore the Liver Cancer Study Group of Japan (LCSGJ)
suggests a tumour cut-off size of 2cm as apposed to the 5 cm suggested by the TNM system [24].
Whilst there is little doubt that the results are superior for small tumours (<5 cm), several
studies have indicated that resection for larger tumours (>5 cm) [27], [28] is beneficial. The
Memorial Sloan–Kettering Group have analyzed the results of resection in 154 patients (out of
total of 412 seen at their institution over a 6 year period) and found that for tumors <5 cm, the
overall 5-year survival rate is 57% and the disease-free survival rate is 44%. Even for those with
large tumors (>10 cm), the 5-year survival rate was 32%, with disease-free survival rate is only
23% [27]. Therefore they concluded that LR was superior to other forms of treatment for larger
tumours and advocated partial hepatectomy as a safe, effective, and potentially curative
therapy of choice for HCC >5 cm. For tumors <5 cm, much more relevant is the comparison
between LR and ablative options. In a comparative study from China of 1000 small tumours
(less than 5 cm) versus 1366 large (more than 5 cm) [28] survival rates after LR at 5 years of
62.7% vs. 37.1% (p < 0.01) and at 10 years of 46.3% vs. 29.2% (p < 0.01) were seen on univariate
analysis. However compared with patients who had large HCC, those with small HCC had a
higher percentage of single tumor nodules (82.6% vs. 64.4%), a higher proportion of well
encapsulated tumors (73.3% vs. 46.3%), a lower proportion of tumor emboli in the portal vein
(4.9% vs. 20.8%) and better differentiation of tumor cells (Edmondson Grade 3–4; 14.9% vs.
20.1%), a higher resection rate (93.6% [1000 of 1068 patients] vs. 55.7% [1366 of 2451 patients];
P < 0.01), a higher curative resection rate (80.5% [805 of 1000 patients] vs. 60.7% [829 of 1366
patients]; p < 0.01) and a lower operative mortality rate (1.5% [15 of 1000 patients] vs. 3.7% [50
of 1366 patients]; p < 0.01). Importantly following multivariate analysis, four independent
covariates negatively influenced the survival rate: γ-glutamyl transpeptidase (more than 6IU/
mL), presence of cirrhosis, multiple tumors, and emboli in the portal vein. Size of lesion was
not an independent predictive factor.
The results of surgery in the so-called giant tumours (>10 cm) which would be exempt from
transplantation, are reassuring too; Chen and co-workers [29] reported on 525 patients with
tumours >10 cm noting a 2.7% perioperative mortality and a 5-year survival of 16.8%. Yeh and
colleagues reported 211 tumours greater than 10 cm in a series of 1196 patients thus repre‐
senting 17.6% of their patients. They noted resection to be safe and feasible with a reasonable
5-year survival of 16.7% for this cohort although this was significantly lower than the 39.5%
documented for tumours less than 10 cm [30]. In a study of 300 patients with tumours >10 cm,
the group from MD Anderson reported a 27% 5-year survival [31]. Therefore the value of
resecting large and otherwise ‘untreatable’ tumours was confirmed. It is clear that prognostic
indicators such as size can be used as a guide in the decision to operate or not, but cannot be
used alone to exclude patients from surgery - such decisions should be based on surgical risk
and resectability.
Vascular invasion: Again from the multi-institutional cohorts (vide supra) the presence of
vascular invasion appears to be an independent predictor of recurrent disease and death after
LR; HR (95% CI) for major vascular invasion – 2.1 (1.4 – 3.3), microvascular invasion – 1.6 (1.2
– 2.1) and 5-year survival with and without macrovascular invasion was 15% versus 41%
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respectively [26]. In a cohort of 322 patients undergoing resection for HCC [32] the 5-year
survival of those with microscopic venous invasion (n = 140) versus macroscopic venous
involvement (n = 50) versus those without any venous invasion (n = 132) was 30.8%, 15% and
50% (p <0.05). Also, larger tumours were associated with higher incidence of venous involve‐
ment. Major vascular invasion (macrovascular invasion) into one of the main portal branches
or a hepatic vein is associated with a worse prognosis, presumably due to intra-hepatic and
systemic dissemination of tumour thrombi. From a multi-institutional study of 102 patients,
major portal invasion was associated with 1-, 3- and 5- year survival of 47%, 17% and 10%
respectively [31], however in the group which had major vascular involvement but without
moderate-severe fibrosis or high nuclear grade 5 year survival was 23% vs 5% and 21% vs 9%
respectively. Therefore the MD Anderson data suggests resection in spite of major vascular
invasion in the absence of moderate-severe fibrosis in the liver parenchyma and absent high
nuclear grade in the tumour. Similarly the incidence of microscopic vascular invasion is
increased with tumor size (≤3 cm, 25%; 3.1-5 cm, 40%; 5.1-6.5 cm, 55%; >6.5 cm, 63%) (p < 0.005)
[33]. Therefore it is clear that tumour size, which can be measured radiologically, is a good
surrogate marker for microvascular invasion, which can only be assessed on the resected
specimen. It is accepted that larger tumours (especially those more than 7 cm) and certain types
of growth patterns (single nodule with extra-nodular growth, contiguous multi-nodular
growth patterns) are highly predictive of microvascular invasion (as compared to a single
nodular type with clear demarcation) in lesions more than 5 cm in size [34]. However increas‐
ing size or number of lesions in the absence of vascular involvement does not impact on
survival [26].
3.2. Tumour number, multifocality and satellite nodules
The number of tumours present is another important factor for not only overall survival [35]
[31] [36] but for disease-free survival [36]- [39] as well.. The AASLD guidelines recommend
LR for a single liver lesion if there is no cirrhosis or significant impairment of liver function [4].
However results from a large multi-institutional cohort study [36] looking at the perioperative
and long-term outcomes of 404 patients with single small HCC (<5 cm) as compared to 380
patients with large or multinodular HCC demonstrated overall survival rates were signifi‐
cantly higher in the small HCC group (1 year, 88% vs. 74%; 3 years, 76% vs. 50%; 5 years, 58%
vs. 39%; p <.001). Among patients with the larger tumours, five independent prognostic factors
were identified to be associated with a worse overall survival: namely, symptomatic disease,
presence of cirrhosis, multinodular tumor, microvascular tumor invasion, and positive
histological margin. Multifocality may be a manifestation of one of 2 differing scenarios: either
multiple foci of primary tumour within an at-risk field or the presence of intrahepatic meta‐
stases from a primary lesion. It is impossible to determine which scenario is being displayed
pre-operatively but the latter carries a significantly worse prognosis.
3.3. Pre-operative Alpha-Fetoprotein (AFP) levels
AFP is a major plasma protein produced by the yolk sac and the liver during fetal development
that is thought to be the fetal form of serum albumin. Its levels decrease rapidly after birth and
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its functions in the fetus are not clearly known. Its levels are raised in HCC and germ cell
tumours. Raised AFP levels have been considered to be a marker of poor prognosis both for
overall survival [37] [27], [40] and disease-free survival [30], [37], [41], [42]. The relevance of
AFP levels has not been addressed specifically in relation to resection although in one study
an AFP level more than 100ng/ml was an independent risk factor [OR (95% CI) 2.56 (1.05 –
6.20)] along with microvascular invasion (OR 4.54 (1.86 – 11.09) in a cohort of small HCC who
underwent curative resection [43]. AFP levels are probably a reflection of tumour biology and
thus a surrogate marker for size/stage of the tumour.
4. Liver specific factors
4.1. Portal hypertension
It is well known that patients with a normal liver tolerate large hepatectomy without significant
risk of liver failure. However, in patients with chronic liver disease the tolerance to liver
resection and long-term outcome is reduced in parallel to the degree of liver function impair‐
ment and appearance of portal hypertension (PHT) [44]. Hemodynamic studies have shown
that the presence of a hepatic vein pressure gradient greater than 10 mmHg is associated with
a higher risk of postoperative liver decompensation and of poor long-term outcome after liver
resection for HCC [45]. Clinically relevant PHT can also be detected by the presence of
esophageal varices or splenomegaly associated with reduced platelet count. Assessment of
presence or absence of PHT is an important step in not only risk assessment and outcome
prediction, but importantly to ascertain suitability for resectional surgery and the extent of
such surgery [46]. Indeed a recent study has suggested that this is an essential part of assess‐
ment of these patients for resection [47]. HVPG is an invasive test but some interest and success
has recently been demonstrated for measurement of liver stiffness by elastography and its
correlation with HVPG [48]. While 5-year survival in patients without PHT exceeds 70%, those
patients with such adverse profile present a reduction to 50–60%. If liver disease is decom‐
pensated (ascites, jaundice), survival is even further decreased. Presence of PHT higher risk
does not translate into absolute contraindication for resection [49], as less extensive resection/
ablation etc. can be considered but the predicted outcome with surgery has to be weighed
against other available treatment options in an individual patient.
4.2. Future liver remnant/ Functional Liver Remnant (FLR)
One of the important limiting factors for LR in HCC is the amount of viable liver parenchyma
left behind- future liver remnant or more appropriately called functional liver remnant (FLR).
In a normal liver, removal of a part of the liver leads to rapid hypertrophy of the remnant to
reach the pre-operative liver-body weight ratio. Adequate FLR is not only an adequate volume
of liver remnant but also a remnant of adequate function sufficient to meet post-operative
physiological demands. Although the removal of up to 75% of the total liver volume is feasible
in a young patient (≤40 years of age) with normal hepatic parenchyma, resection must be more
conservative in the presence of underlying liver diseases (steatosis, steato-hepatitis, fibrosis,
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cirrhosis, cholestasis, chemo-therapy induced liver injury), elderly patients and in the setting
of excessive intra-operative blood loss [50]. An adequate FLR is generally considered to be
around 25%, 30% and 40% of the pre-operative liver volume in normal [51], steatotic and
cirrhotic livers [52] respectively, although it is accepted that volume is a poor correlate of
function in livers with chronic disease. Below a certain threshold, a liver remnant cannot
sustain metabolic, synthetic and detoxifying functions and liver failure results leading on to
the spiral of cholestasis, coagulopathy, sepsis, multiple organ failure and potentially death.
Various techniques of assessing the FLR have been described including assessment of volume
using axial imaging e.g. triple phase CT Liver, and MR Liver. Dynamic quantitative liver
function tests, such as the indocyanine green test and galactose elimination capacity, are more
accurate as they measure the elimination process of a substance that is cleared and/or metab‐
olized almost exclusively by the liver. However, these tests only measure global liver function.
Nuclear imaging techniques (Tc-galactosyl serum albumin scintigraphy and Tc-mebrofenin
hepatobiliary scintigraphy) can measure both total and future remnant liver function and
potentially identify patients at risk for post resectional liver failure [53]. A novel technique
described has been the utilization of a combination LiMAX test (Liver MAximum capacity)
and (triple phase CT, 3-D analysis – MeVIS, CT volumetry and virtual resection) and to
successfully predict FLR and postoperative outcome after hepatectomy pre-operatively [54].
Preoperative portal vein embolization of the lobe free of disease may induce compensatory
liver growth, allowing resection of larger volumes of tumour bearing liver [55] [56]. Indeed
pre-operative selective internal radiotherapy (SIRT/Transarterial radioembolization – TARE)
is being used to down-size liver tumors [57] including HCC [58] and increase FLR prior to
major hepatectomy.
5. Liver resection for HCC — Technical considerations
Both non-cirrhotic patients and cirrhotics could be subjected to surgical resections as long as
liver function was well-preserved and tumor had low burden (ideally single tumor). Usually,
best results of surgical approaches are obtained in experienced centers with a perioperative
mortality of less than 3% and a 5-year survival rate higher than 50% [6]. The correct selection
of candidates is very important for the outcome and all issues discussed above need to be
considered. Historically, patients with HCC and cirrhosis had a worse prognosis after LR but
those without extrahepatic disease and small tumours had early mortality much lower than
that reported for LT. Mortality rate related to LR in non-cirrhotics is approximately 1% [59].
The most common causes of death following LR are postoperative haemorrhage, liver failure
and sepsis, even in well-compensated Child’s A or B cirrhotics. Extended left and right
hepatectomy are well documented in cirrhotic patients with low complication rates, ensuring
a sufficient remnant hepatic function. The improvements of surgical techniques (e.g. Pringle’s
manoeuvre, anterior approach, low CVP anaesthesia), a better Knowledge of Couinaud’s
segmental anatomy, the development of ultrasonic dissectors and vascular staplers have
contributed to reduce postoperative morbidities, including bleeding complications. Therefore
LR for HCC should be an important treatment modality in the current era.
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5.1. The anterior approach and the hanging manoeuvre
During right hepatic resection for hepatocellular carcinoma (HCC), complete mobilization of
the right lobe of liver with the right hepatic vein controlled outside the liver before parenchy‐
mal transection had been advised by most surgeons in an effort to reduce blood loss. However,
this can be difficult, when resection for large HCC is being performed. The size of the tumor
may limit access to the posterior aspect of the right lobe of liver and the anterior surface of the
inferior vena cava, where the right hepatic vein and many caval branches are present. Injudi‐
cious mobilization and forceful retraction of the liver may cause profuse bleeding from
avulsion of the hepatic vein and caval branches, prolonged ischemia of the liver remnant from
rotation of the hepatoduodenal ligament iatrogenic tumor rupture, and scatter of tumoural
cells into peripheral blood. Alternatively, the anterior approach can be used in the more
difficult cases of right hepatic resection for HCC. The technique implies initial completion of
parenchymal transection before the right lobe is mobilized. Briefly following laparotomy,
intra-operative ultrasonography and hilar dissection to control the right hepatic artery and
portal vein, mobilization of the tumor and the right lobe of liver is not performed as in the
conventional approach. The plane of parenchymal transection, depending on the extent of
hepatic resection, is marked on the Glisson capsule with the help of intraoperative ultraso‐
nography and transection carried out from the anterior surface of the liver down to the right
side of liver hilum and down to the anterior surface of the inferior vena cava. The right hepatic
vein is then isolated, clamped, divided, and sutured outside the liver parenchyma. When the
specimen is completely disconnected from the inferior vena cava, the right hepatic lobe is
mobilized from the right abdominal cavity by dividing the triangular ligament and other
posterior attachments [25], [60]. This technique pioneered from Hong Kong demonstrated
significantly fewer intraoperative haemorrhages and blood transfusions, a lower hospital
death rate, a lower incidence of pulmonary metastases, and a better median disease-free
survival and median overall cumulative survival in n=54 patients as compared to patients who
underwent conventional approach n=106 to major liver resection for HCC more than 5 cm in
size [25]. A randomized controlled study from the same institute reported better operative
(lower blood loss, lower transfusion requirements, lower plasma albumin mRNA levels) and
survival outcomes [lower in-hospital mortality 91/60 vs. 6/60), overall survival but not disease
free survival] from anterior approach compared with the conventional approach [61]. How‐
ever the anterior approach can potentially be dangerous” because “torrential bleeding can
occur at the deeper plane of parenchymal transection” and “without prior mobilization of the
right liver and the tumor, and control of the right hepatic vein, bleeding can be substantial and
difficult to control. Therefore the anterior approach can be an effective alternative when
difficulty is encountered during liver mobilization utilizing the conventional technique [62].
5.2. Anatomic (AR) vs. Non-Anatomic Resections (NAR)
Microportal invasion and intrahepatic metastasis were considered to be the most important
factors leading to recurrence and were associated with poor prognosis [26], [63], [64]. Therefore
anatomic resection [65] (AR), which is the systematic removal of a hepatic segment/s bearing
the tumour/s. Theoretically, this procedure may be effective in eradicating intrahepatic
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metastasis of HCC, leading to more favorable results in HCC patients. Although some authors
have reported that AR may prevent hepatic recurrence and prolong survival [7–9], others have
failed to detect survival benefits of AR [10–12]. Thus, the superiority of AR compared to non-
anatomic resection (NAR) remains controversial. A recent metaanalysis of 16 nonrandomized
studies involving 2,917 patients (AR n=1,577 vs NAR n= 1,340) reported that AR was charac‐
terized by better survival and lower local recurrence rates than NAR for the treatment of HCC
[66]. Patients in the AR group had lower prevalence of cirrhosis and hepatitis virus infection,
better liver function, and larger tumor size compared with patients in the NAR group. AR
provided a better 5-year overall survival than NAR (OR, 1.63; 95% CI, 1.15-2.32). Local
recurrence (OR, 0.28; 95% CI, 0.16-0.50) and early (≤2 years) recurrence (OR, 0.55; 95 CI,
0.34-0.89) were all significantly lower in the AR group. AR improved disease-free survival
significantly at 3 years (OR, 2.09; 95% CI, 1.52-2.88) and 5 years (OR, 2.24; 95% CI, 1.85-2.72).
There were no differences regarding postoperative morbidity, mortality, and length of hospital
stay between two groups. However another metaanalysis reported on nine comparative
studies comprising 1,503 patients (833 AR and 670 NAR) [67]. In the combined results, disease-
free survival was significantly higher in the AR group than in the NAR group (OR 1.78, 95%
CI 1.22-2.59, P = 0.003; heterogeneity P = 0.08). Given the heterogeneity in the studies the
authors cautioned against acceptance of the results. Presence of cirrhosis is a well-established
risk factor not only for both hepatocellular carcinoma occurrence but also for recurrence after
hepatic resection [2, 4, 5] in comparison to chronic hepatitis without cirrhosis. Since most of
cirrhotic patients were submitted to NAR to save the liver parenchyma as much as possible to
avoid postoperative liver failure, the end result of Zhou et al. is a natural consequence of this
fundamental bias of the study population therefore the jury regarding the superiority of AR
for HCC is still out [68].
5.3. Laparoscopic liver resection for HCC
Laparoscopic liver resection (LLR) was first reported in the early nineties as a novel procedure
and initially adopted for non-anatomical liver wedge resection for peripheral benign tumors
[69]. With increasing advances in instrumentation and techniques, LLR has been established
as a safe and feasible option for both benign and malignant liver lesions. A world review of
laparoscopic liver resection (2804 patients, 127 published papers, both malignant and benign
tumours) demonstrated that the procedure in experienced hands carries an acceptable
morbidity and mortality for both minor and major hepatectomy [70]. Intuitively it does appear
that for patients with a solitary HCC <5 cm in the periphery of the liver i.e. segments 2, 3, 4b,
5, and 6, compensated liver disease in the absence of significant portal hypertension, LLR has
an important role. A number of advantages have been recognized when comparing LLR vs
LR from case-matched analyses [71], [72] and case series - including reductions in postopera‐
tive pain, less blood loss, lower blood transfusion requirements, less operative morbidity [71],
and shorter length of hospitalization [71] with similar long-term outcomes [71] especially for
cirrhotic patients [72]. However to date there are no randomized trials comparing these 2
modes of surgery.
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At least 3 different meta-analyses [73] [74], [75] have been published in the last 20 months
comparing available evidence for and against LLR vs LR for HCC. All 3 analyses concluded
that LLR results in less blood loss, decreased rate of intraoperative transfusion and shorter
lengths of hospital stay with no adverse impact long-term oncologic outcomes or increased
risk of tumor recurrence. In fact for tumours in the periphery of the liver, resection can be
performed with reduced mortality and morbidity and equivalent oncologic outcomes, disease-
free survival, and overall survival when compared with similarly selected cirrhotic patients
undergoing open resection [76].
Importantly, because HCC recurrence remains high in the cirrhotic liver, treatment following
surgical resection mandates routine surveillance and further treatment of the recurrence either
by locoregional therapy, re-resection, or transplantation as appropriate - the latter two of which
are facilitated by an initial laparoscopic resection [76], [77].
6. Long-term outcome after liver resection for HCC
The majority of patients presenting with hepatocellular cancer are inoperable, largely due to
extent of disease and poor liver function. The overall resection rate is <40% with a long term
survival – of no more than 15%, due largely to the high post op mortality rate, intra-hepatic
recurrence, distant metastases, progressive liver disease and the lifelong risk of hepatitis –
although the new treatment options now available may reduce the risk in the long term.
Reviewing survival after resection for HCC in 17 series reported since 2000, each of which
included more than 100 patients Takayama [78] et al. reported median survival rates of 80%
(range 63 – 97%) at 1-year, 70% (34 – 78%) at 3 years and 50% (17–69%) at 5 years. Such wide
ranges of survival rates are attributed mainly to differences in the HCC stage among the
studies, but the survival rate is obviously much better for early-stage HCCs [79].
There is a large variation in the mortality rate following resection due to differences in
definitions thus making inter-series comparisons difficult, this being further complicated by
the mix of cirrhotic and non-cirrhotic patients, and various distributions of Child-Pugh status.
Irrespective of the presence or absence of cirrhosis, the median perioperative mortality rate
either 30 day or in-hospital mortality was a median of 4.7% with a range from 0 to 21.1%, with
lower rates seen in series with larger volumes irrespective of underlying liver disease [80].
HCC frequently recurs after curative liver resection. The post- operative 5-year recurrence rate
is 77–100%, and median survival after recurrence is 7–28 months [81]. Nonetheless, the long-
term survival after hepatectomy remains unsatisfactory because of the high incidence of
recurrence. Intrahepatic recurrences are the most common and are seen in up to 36.8–78% of
patients [82]. About 80% of recurrent tumors develop exclusively within the liver, and only
20% of such tumors are resectable. As a treatment option, repeat liver resection has plays an
important role in selected patients, yielding results similar to those after primary resection,
with a 5-year survival rate of about 50%. Japanese authors have proposed that repeat resection
is indicated for the treatment of recurrence in patients with a single HCC at the first resection,
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a disease-free interval longer than 1 year and recurrent HCC with no portal invasion [78]. In
patients who met these criteria, the 5-year survival rate was 86% after the second resection [83].
Predictors of poor outcomes in HCC are common to all therapeutic approaches and include
more than three tumors, a tumor size larger than 5 cm, portal vein invasion, intrahepatic
metastases, absence of a tumor pseudocapsule, advanced TNM stage (III or IV), Hepatitis C
viral infection [84] and a Child – Pugh class of C [85]. The most important factors appear to be
vascular invasion and liver function [86].
7. Liver resection prior to liver transplantation (Salvage liver
transplantation)
Resection can be used as a treatment for HCC prior to LT in three different settings. First,
resection can be used as a primary therapy, and LT reserved as a ‘‘salvage’’ therapy for patients
who develop recurrence or liver failure. Second, resection can be used as an initial therapy to
select patients who might get benefit from LT, according to detailed pathological examination
of the tumor and the surrounding liver parenchyma. Third, resection can be used as a ‘‘bridge’’
therapy for patients who have already been enlisted for LT. Salvage LT has been performed
for recurrent HCC or deterioration of liver function after primary liver resection.
Resection as the first-line treatment for patients with small HCC with preserved liver function,
followed by salvage transplantation only for recurrence or liver failure is an attractive option.
Initial resection, which should be preferably an anatomic resection, gives rapid access to an
effective therapy, without the need for a donor, and offers 5-year survival rates exceeding 50%
with a good quality of life [87]. The main obstacle to this strategy is the risk of ‘‘loss of chance
of cure’’ in case of rapid and extensive recurrence not amendable to salvage LT. At the time of
recurrence, salvage LT is only applicable/gives best results in patients with a tumor within the
Milan criteria.
Another justification for resection prior to transplantation is that it helps refine the selection
process, giving access to detailed pathological examination of the tumor and the surrounding
liver parenchyma. Important prognostic information can be obtained, including differentia‐
tion, presence of satellite nodules, and the presence of microvascular and capsular invasions.
As a result, resection may help avoid transplantation in patients with tumors apparently within
the Milan criteria but with histological features of especially poor prognosis. In contrast,
resection may help decide on transplantation in patients with tumors slightly outside the Milan
criteria but with histological features of good prognosis.
Resection can also be used as a ‘‘bridge’’ therapy in patients already enlisted for LT. TACE
and radiofrequency ablation, which are the mainstays of ‘‘bridge’’ therapies, can be chal‐
lenged  by  resection,  which  provides  the  best  control  of  the  tumour,  allowing  accurate
histological assessment of both the tumour and the underlying liver status. Although limited
resection appears to be sufficient in this setting, it is associated with increased risk and is only
appropriate for patients with peripheral tumours and Child A cirrhosis. The subsequent LT
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may be made more difficult. The use of laparoscopic or transthoracic approaches for periph‐
eral tumours may further contribute to expand this strategy by minimizing technical difficul‐
ties  during  the  transplant  procedure  (vide  supra).  An  important  consideration  is  that
significant  adhesions  and  anatomical  distortion  exist  in  the  abdomen  following  LR,  al‐
though LLR seems to have a benefit to facilitate later LT by reducing these (vide supra).
Although it has been claimed that prior LR neither increases operative morbidity nor impairs
survival following cadaveric LT [88], this strategy is by no means universally acceptable [89].
This is due to LT after liver resection being associated with a higher operative mortality, an
increased risk of recurrence, and a poorer outcome than primary LT [89]. In addition, liver
resection as a bridge to LT impairs the patient transplantability and the chance of long-term
survival of cirrhotic patients with HCC [89]. Indeed a recent comparative analysis of prognos‐
tic factors for HCC recurrence in a Western and an Eastern HCC patient cohort revealed on
multi-variate analysis that that our independent risk factors for post-LT HCC recurrence:
micro- vascular invasion (odds ratio, OR = 4.88; p = 0.001), poor tumour grading (OR = 6.86;
p = 0.002), diameter of the largest tumour (OR = 4.72; p = 0.05), and previous liver resection
(LR) (OR = 3.34; p = 0.04) [90]. It is therefore suggested that primary LT should therefore remain
the ideal  choice of  treatment of a cirrhotic patient with HCC, even when the tumour is
resectable.  The salvage LT strategy should therefore be restricted to those patients  with
favourable oncological factors, thereby excluding patients with poor tumour grading, vascular
invasion, diameter >3 cm and presence of satellite nodules at pathological examination, as
recently suggested by the Belghiti group [91].
8. Liver transplantation for HCC
Liver transplantation (LT) is the treatment of choice for Child B and C patients with HCC but
LT is limited by the lack of donor organs (demand exceeds availability) and the therapy cannot
be given immediately (at least in the cadaveric LT setting)! One of the consequences of this
shortage is that access to transplantation is usually restricted by rules that take into account
need, transplant benefit, utility and distributive justice.
Liver transplantation for HCC before 1995 yielded disappointing results; 2-year survivals were
30% or less [92], [93], 3-year survival 3-year survival rates of 21% to 47% and the recurrence
rates were high after transplantation (29% to 54%) [94]. These results were due to a bias toward
performing transplantation for patients with unrespectable tumours. Through the 1980s and
early 1990s, hepatic resection remained the treatment of choice for patients with early HCC
and enough hepatic reserve to tolerate resection. Therefore, transplantation was often left to
those with unresectable tumours (large, multiple, or both). The disappointing results called
into question the value of transplantation for HCC [95]. However, within the total cohort of
HCC patients who underwent transplantation, centers also reported on subgroups with early-
stage disease that did well [96], [97]. Specifically, it was known that patients who had under‐
gone transplantation and were found to have incidental small HCCs on histological
examination of the explanted liver had excellent disease-free survival [98], [99].
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In the current era the benchmark for LT in HCC is the Milan criteria. Following years of
unrestricted use of LT for HCC with survival post LT being dismal (vide supra), the Milan
criteria were introduced [100]. This prospective study included single tumours up to 5 cm or
up to 3 tumours each not more than 3 cm and after four years their actuarial survival rate was
75%, the rate of recurrence-free survival was 83% and recurrence was seen in 8%. These results
have been duplicated other in large cohorts [101] [102]. The Milan criteria have been widely
implemented - the TNM staging system was modified such that T2 corresponds to the Milan
criteria, UNOS has adopted these changes into their policy on recipient prioritization for liver
transplantation and the BCLC staging system has incorporated the Milan Criteria into tis
algorithm.
9. Assessment of candidates for LT
Staging of HCC patients (Table 1) should not only assess the tumour in the liver but also take
into account the background liver disease and their performance status [103]. This will improve
the accuracy of prognostication and enable selection of specific treatment alternatives.
Despite significant technological advances in cross-sectional imaging techniques (ultrasonog‐
raphy, CT, and MRI), standard imaging methods can underestimate or overestimate the extent
of HCC in up to 25% of cases, compared with pathological findings of the explanted liver [104].
Conclusive imaging features rely on the presence of arterial enhancement followed by washout
on portal venous or delayed imaging [105]. Dynamic CT or MRI, including unenhanced,
arterial, portal venous, and delayed phases, provide improved sensitivity and specificity as
compared with standard techniques of the past. Currently, there is no data showing the
superiority of either MRI or CT. Dynamic ultrasonography has improved the accuracy of ultra
sonography, but is less useful than CT or MRI because of the inability to reliably acquire images
of the entire liver during a particular contrast phase. The American Association for the Study
of Liver Disease (AASLD) has proposed an algorithm for diagnosis of HCC based on availa‐
bility of state-of-the-art CT or MRI [106]. Bone scintigraphy has been used for evaluating bone
metastases; however, the technique is poor in terms of cost-effectiveness when used routinely.
There is insufficient data to propose [18] F-fluorodeoxyglucose (FDG)-PET for staging HCC
before liver transplantation although PET scans using other isotopes (carbon-11, Fluorine-18
choline) have been utilized in staging HCC [107].
10. UK guidelines
The criteria first published in 2003 [108] for selection to the transplant list for cases with HCC
has recently been revised. The current UK guidelines from May 2008 [109] (UK Guidelines for
the management of suspected hepatocellular carcinoma (HCC) in adults) advise the following:
1. Radiological assessment should include both multidetecor (MD) CT and MRI, with size
assessed by the widest dimensions of the neoplasm on either modality.
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2. A lesion (for the purposes of counting numbers) will require to be identified as an
arterialised focal abnormality with portal phase washout on MDCT or Gd enhanced MR.
Other lesions are considered indeterminate.
3. Tumour rupture and an AFP > 10,000 IU/l are absolute contraindications to transplanta‐
tion, as are extrahepatic spread and macroscopic vascular invasion.
4. The following are criteria for listing for transplantation; standard Milan criteria or the new
UK criteria, which include: up to 5 lesions all < 3 cm single lesion > 5 cm < 7 cm diameter
where there has been no evidence of tumour progression (volume increase by <20%; no
extrahepatic spread; no new nodule formation) over a 6 month period. Locoregional +/-
chemotherapy may be given during that time. Their waiting list place may be considered
from the time of their first staging scan.
5. Locoregional therapy should be considered for all transplant list cases.
6. Cases outwith current proposed selection criteria will not be selectable on to the transplant
list after their tumour has been downsized by surgical or loco-regional treatments.
When utilising staging systems; clinical based systems are probably of greater use rather than
the TNM (pathological classification) or the upto-7 criteria [110] (which relies on micro-
vascular invasion) given that clinical decisions can be made more appropriately and prognostic
information can be provided in counselling patients for such treatment. This is where the BCLC
treatment algorithm becomes useful and indeed has been validated in cohorts outside of spain
for this purpose. The International consensus report [103] recommended the use of BCLC
staging system when considering treatment options (Evidence level 2b Strong recommenda‐
tion) and the TNM system to assess prognosis after transplantation (Evidence level 2b Strong
recommendation).
11. Role of tumour biopsy
A tissue diagnosis of a suspicious liver lesion would be an ideal guide to appropriate treatment
in the setting of equivocal imaging and serology. Increasing advances in imaging (scanning
machines and techniques) resulting in better discrimination of hypervascular lesions into HCC
or other tumours has resulted in a decreasing need for pre-listing biopsy of tumours suspect‐
ed of being HCC. The accuracy of cross-sectional imaging in diagnosing small malignant liver
tumours (less than 2 cm), especially in the cirrhotic liver, however, remains problematic with
sensitivities for MRI detection of such lesions being 13–67% and approaching 100% for lesions
more than 3 cm [111] [112] [113]. Therefore the European Association for the Study of the Liver
(EASL) permitted needle biopsy of lesions ranging from 10 to 20 mm in diameter in patients
with cirrhosis [114] this has however been updated in 2012. Tumour biopsy is not required in
cirrhotic patients considered for liver transplantation who have high-quality dynamic CT or
MRI findings typical for HCC and a lesion larger than 1 cm according to current AASLD
guidelines [106]; and for patients with lesions smaller or equal to 10 mm or atypical find‐
ings, non-invasive imaging does not allow an accurate diagnosis, and should not be used to
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make a decision for or against transplantation. These recommendations were incorporated
into  the  2012  International  consensus  conference  report  [103]  and  EASL endorses  these
guidelines [115].
A systematic review [116] of 8 studies (none were RCT) revealed a needle track risk of seeding
of 2.7% (CI 1.8 – 4) overall or 0.9% per year with a median time of about 17 (IQR 7- 48) months.
However whether this risk does impact on treatment delivery and outcome from it is open to
question [117]. In addition tumour biopsy has other limitations: The specificity of liver biopsy
is close to 100%, but sensitivity varies depending on location of the tumour, needle size (86–
90% with an 18 gauge cutting needle, 67% with 21–22 gauge needle), and tumour size (>90%
for nodules >1 cm vs 83% for nodules <1 cm) [103] [118], [119]. A positive tumour biopsy is
clinically relevant to rule in a diagnosis of HCC, but a negative biopsy is less useful. It is
however clear that in the presence of unequivocal evidence i.e. AFP levels greater than 400 ng/
L and imaging characteristics in a patient with known cirrhosis, there is no need for tumour
biopsy according to the UNOS recommendations.
The recently updated European clinical practice guidelines for the management of HCC [115],
referred to above, highlight the importance of preventive strategies and implementation of
surveillance in those at risk. Surveillance with either USS or a combination of USS with serum
alpha-fetoprotein is widely adopted with the intention of detecting early tumours in patients
fit enough for surgical treatment. The diagnostic criteria for HCC as referred to in the consensus
document are summarised in Table 2.
Size of nodule Cirrhotic patient only
Nodule <1cm 4 month recall
Nodule 1-2cm Non-invasive criteria i.e. typical features on one imaging technique, or biopsy
Nodule >2cm Non-invasive criteria, with biopsy if atypical radiological features or uncertainty.
Table 2. Table for Diagnosis of HCC
Non-invasive criteria can only be applied to cirrhotic patients and should be based on triple
or 4-phase CT scan or dynamic contrast enhanced MRI. The typical radiological hallmark of
HCC is a hypervascular lesion relative to non-tumour liver in the arterial phase of a scan, with
subsequent washout in venous or delayed phases. If features are suboptimal on one imaging
modality, especially for small lesions, a second imaging technique (i.e. MRI + CT, not contrast
enhanced USS) is recommended. In pathological diagnosis, in addition to assessment by an
expert liver histopathologist, immunostaining for glypican-3, glutamine synthase are recom‐
mended to differentiate high grade dysplastic nodules from early HCC. In non-cirrhotic
patients with a suspicious liver nodule (s), biopsy of non-tumour and tumour liver should be
performed to confirm the diagnosis in patients who are candidates for treatment.
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12. MELD prioritization points
Following publication of the Milan criteria, the suitability of certain patients with HCC for
LT led to an increasing number of patients being put forward for this procedure during the
1990s and early 2000s. Increasing demand and shortage of available organs led to long waiting
times and stage progression for these patients with HCC whilst on the W/L leading them
becoming unsuitable for Tx; in Spain the wait time increased from 62 to 162 days [44] and in
the USA 25% of HCC patients dropped off the list every year [120]. When the MELD-based
prioritization system for liver transplantation replaced the Child-Pugh system in February
2002, patients with HCC were given prioritization points as the MELD was not affected by
the presence of HCC. Earlier under the CTP system patients with T2 or lower HCC were
moved  into  a  higher-priority  group  (status  2B),  but  waiting  time  within  the  group  re‐
mained a significant factor and that was perceived as a significant injustice to HCC pa‐
tients. Under the MELD prioritization the system initially gave additional points (up to 24
for T1 HCC and 29 for patients with T2 HCC) with extra points being added every 90 days
spent on the waiting list - to represent a 10% increase in mortality. Although the average
waiting time decreased from 2.28 years before the MELD system to 0.69 years under MELD,
and >85% of HCC patients waited less than 90 days for transplantation and Tx for HCC tripled
it went too far. Non-HCC patients with MELD scores of 24 to 29 had a higher chance of dying
or dropping off the list because they often had more significant hepatic decompensation than
HCC patients with MELD plus points. Also, the increase in transplantations for HCC had an
adverse effect on organ allocation [121]. Fourteen percent of transplants performed for HCC
had no HCC on explant histology in the first 8 months of MELD system [122]. This pre-
transplantation false-positive diagnosis occurred more often for small, single lesions (e.g.,
T1). Moreover, data from the pre-MELD era indicated that patients with T1 lesions had less
than a 10% risk of dropout in the first year listed. Conversely, patients with T2 lesions were
responsible for much of the poor intention-to-treat outcomes under the old system [123].
Because of these data, the assigned MELD scores for patients with HCC were decreased to
20 and 24 for T1 and T2 lesions, respectively, in April 2003. Therefore the assigned MELD
scores for patients with HCC were decreased to 20 and 24 for T1 and T2 lesions, respective‐
ly, in April 2003. This change decreased the proportion of transplantations performed for
HCC from 21% to 14% [122]. Before MELD, the rate was 8%. More recently, the score upgrade
for T1 lesions (20 points) was eliminated, so that now only patients with T2 lesions may
receive a score upgrade (initially 24 points and now 22 points). The effects of these changes
are not yet known.
Expansion of Milan criteria: Proponents of expanding the current criteria are driven by the
increasing number of HCC patients in need of treatment and the observation that some
patients with tumour burdens exceeding the Milan criteria do have long, disease-free survival
after  transplantation.  Several  studies  have  reported  a  good  outcome  for  some  patients
transplanted outside these conventional criteria and the nature of these criteria has been
challenged for being too strict, because they exclude specific subgroups with meaningful,
although lower, chances to benefit from transplantation. Furthermore, some patients might
be excluded from transplantation as a result of the improvement in the accuracy of imaging
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techniques that enable the identification of very small lesions (<1 cm), which were undetecta‐
ble a decade ago. Most of the studies on patients exceeding Milan criteria, however, are
retrospective, with only a small number of patients, disease of variable severity, and short
follow-up [124] [6], [125] [126].
In the context of shortage of available grafts, decisions have to take into account the collective
benefit of all potential liver recipients, in addition to the benefit for the individual patient. Even
though a survival opportunity considerably lower than that achieved in non-HCC patients
might be considered worth the risk of surgery for some patients with HCC, the negative effects
on others on the donor list must be taken into consideration. The international consensus group
[103] recommended that liver transplantation should be reserved for HCC patients who have
a predicted 5-year survival comparable to non-HCC patients.
Milan criteria 5-year survival
Single tumour ≤ 5cm 85%
Not more than 3 tumours, largest ≤ 3 cm
UCSF
Single lesion ≤ 6.5 cm 80%
Multiple lesions ≤ 3 cm
Largest tumour diameter if multiple ≤ 4.5 cm
Total tumour diameter if multiple ≤ 8 cm
UK criteria
Single lesion lesion > 5 cm < 7 cm diameter where there has been no evidence of tumour
progression (volume increase by <20%; no extrahepatic spread; no new nodule formation)
over a 6 month period.
If multiple, up to 5 lesions all < 3 cm
Metro-ticket (up-to 7 criteria)
Single tumour 7 cm 71%
Multiple tumours seven as the sum of the size of the largest tumour [in cm] and the number
of tumours
* All survival figures depend on absence of vascular invasion. The metroticket model can predict for 3- and 5-year survival
with and without vascular invasion (http://www.hcc-olt-metroticket.org/calculator/)
Table 3. Liver Transplantation criteria for HCC
The UCSF group found that patients who had undergone transplantation with single tumours
up to 6.5 cm or no more than 3 tumours with maximum sum of diameters up to 8 cm and no
tumour larger than 4.5 cm had acceptable disease-free survival, similar to that of patients who
met Milan criteria [126]. This data was based on explant histology sizing and not on pretrans‐
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plantation imaging. A follow-up study on a larger number of patients confirmed an acceptable
5-year disease-free survival of 88.5%, compared with 93.8% for those who met Milan criteria
[123]. These findings have been subsequently prospectively validated based on pre-operative
imaging too [127]. Numerous other expansions of Milan have been proposed including single
lesions - 6 cm or up to 3 tumours, but none more than 5 cm where recurrence-free survival was
70% at 3 years [128], and the Up-to-seven criteria (Metroticket prognostication model -
hepatocellular carcinomas with seven as the sum of the size of the largest tumour [in cm] and
the number of tumours with or without vascular invasion) where a 5-year overall survival of
71 2% (64 3–77 0) was seen [110]. But these have not been validated prospectively. Therefore
the international consensus group [103] recommended only modest expansion of the Milan
criteria (in line with UCSF recommendations) but emphasised that this should occur on the
background of an individual centres waiting list of non-HCC patients, waiting list mortality
and the loco-regional scarcity/abundance of donor organs.
13. Role of downstaging
An attractive strategy to improve the results of liver transplantation for expanded criteria HCC
is downstaging to within Milan criteria using loco-regional therapy. The goal of downstaging
using therapy, as alcohol injection, radiofrequency ablation (RFA), transarterial chemoembo‐
lization (TACE), transarterial radioembolisation/selective internal radiotherapy (TARE/SIRT),
or liver resection, is to decrease the tumour size and number in patients initially presenting
with tumours that do not meet locally acceptable criteria for liver transplantation.
Theoretically, a downstaged tumour may carry a reduced risk of posttransplant recurrence
comparable to that of one initially within the Milan criteria. More importantly, downstaging
may allow selection of tumours with more favourable biology that respond well to treatment
and also do well after liver transplant.
Two prospective studies showed that survival after liver transplantation in patients with large
tumour burden successfully treated by downstaging was similar to survival in patients who
initially met the criteria for transplantation. Pinna et al. compared the outcome of patients
down-staged from outside Milan (n=48) to those within Milan (n=129) and reported similar LT
rates (67 vs 68%), 1- and 3-year survival rates (71% vs 80% and 71% vs 78% respectively)
between the 2 groups with no significant difference in actuarial intention to treat survival
between the 2 groups (56.3% vs 62.8%) [129]. Forty-three patients were downstaged to meet
the Milan criteria with a combination of liver resection, local ablation or TACE. Ten patients
dropped out before transplantation due to liver failure (n = 2) or tumour progression (n = 8)
and 32 underwent liver transplantation. The rate of dropout due to cancer progression was,
as expected, higher in the downstaging group (27.1% vs. 11.6%) with more advanced HCC
and the dropout should be regarded as a part of the selection process in order to achieve an
acceptable posttransplant outcome in these patients. The authors rightly stated in the discus‐
sion, ‘we clinically selected the HCCs with a more favourable biology’. Interestingly in this
series nearly 70% of the patients in this series of expanded criteria recipients had serum
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alphafetoprotein < 30 ng/mL. Serum alphafetoprotein has been found to be an important
prognostic indicator for patients with HCC after liver transplantation and the incorporation
of serum alphafetoprotein into a scoring system [130] as selection criteria can help to identify
the high-risk, high-volume HCC for exclusion and the low-risk, low-volume HCC [131] for LT
after down-staging. It is likely that downstaging may simply provide another mode of selection
but its advantage over more simple selection criteria such as tumour size and number,
histologic features or serum alphafetoprotein remains to be confirmed by further studies.
In another prospective study [132], 43/61 (70.5%) patients were downstaged (TACE and RFA)
to UNOS criteria (vide supra) and after 3-months of progression free interval, 35(57.4%)
underwent LT. Treatment failure was observed in 18 patients (29.5%), primarily due to tumour
progression. In the explant of 35 patients who underwent LT, 13 had complete tumour necrosis,
17 met T2 criteria, and five exceeded T2 criteria and none demonstrated microvascular invasion
or poorly differentiated disease. The Kaplan-Meier intention-to-treat survival at 1 and 4 years
after down staging were 87.5% and 69.3%, respectively. The 1-year and 4-year post transplan‐
tation survival rates were 96.2% and 92.1%, respectively. No patient had HCC recurrence after
a median post transplantation follow-up of 25 months. The only factor predicting treatment
failure was pre-treatment alpha-fetoprotein >1,000 ng/mL. The main thrust of this study
appears to suggest that using response to locoregional therapy to select transplant recipients
provides an attractive alternative to simply expanding the existing criteria.
14. Managing patients on wait-list for LT
One of the consequences of waiting for transplantation is that during this time, the disease
may change or in other words allow the true biological nature of the neoplasm to be expressed
thereby aiding improved selection of patients for LT. Also the waiting time in which the disease
can evolve allows treatment strategies, which can be implemented to influence its course. The
seminal article of the BCLC study group [44] which compared the intention- to-treat (ITT)
outcomes of resection and transplantation for HCC, identified that the concept of dropout on
the waiting list was crucial, and it has become the equivalent of the risk of pretransplant
mortality addressed by the Model for End-Stage Liver Disease (MELD) priority system for
non-HCC patients. Therefore managing patients involves minimizing the drop-out rate and
successfully “bridging” patients to a LT.
The term “bridging” is for strategies that are implemented in patients who already qualify for
LT according to the accepted selection criteria so that they can wait until a graft is available.
A bridging strategy can be effective because (1) it allows candidates to wait for a longer time
or more candidates to wait for the same time (or both) or (2) it improves the results of trans‐
plantation by excluding patients whose disease will recur or by stopping the progression of a
tumour before extrahepatic spread has occurred. The word “down-staging” refers to the
reduction of the clinical stage of a disease from any initial stage (e.g., from T2 to T1), down-
staging in the context of LT for HCC is used for strategies allowing the transplantation of
patients who at first do not qualify for OLT because their tumours are outside the accepted
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criteria (T3 or higher). Down-staging strategies may use the same neoadjuvant treatments that
are used in bridging strategies.
Therefore the aims of managing patients whilst on a wait-list i.e. bridging strategies are
1. For patients to remain good candidates until a graft is available.
2. For the transplant program and society to exclude poor candidates even though on entry
they fulfilled restrictive selection criteria.
3. To improve the results after transplantation.
4. To be compatible with a treatment other than transplantation in the case of dropout.
5. To have an optimal cost and complication/effectiveness ratio.
Managing patients while they are waiting for a liver graft to become available involves
monitoring not only the tumour but also the background liver disease. With increases in
waiting times for liver transplantation, it is common practice to monitor patients with HCC to
ensure that they remain within the acceptability criteria for liver transplantation. Both imaging
and measurement of AFP levels are commonly utilised. There is no agreement about specific
timing or optimum imaging methods (dynamic CT, dynamic MRI, or contrast-enhanced
ultrasonography). In our Unit a 3-month interval between surveillance scans whilst on the
wait-list is adopted.
Locoregional therapies represent bridging strategies for patients on the waiting list, because
they can decrease tumour-related dropout rates and the incidence of recurrences after liver
transplantation, above all for patients that have to wait 6 months or longer [133]. There is,
however, no evidence that bridging strategies could be helpful in patients with United
Network for Organ Sharing (UNOS) T1 tumours (<2 cm). Bridging strategies might be
appropriate for patients with UNOS T2 lesions (one nodule 2–5 cm or three or fewer nodules
each ≤3 cm) who are likely to wait 6 months or longer. Therefore a recent consensus conference
[103] (clavien PA Lancet Oncol 2012) concluded that in patients with UNOS T2 (one nodule
2–5 cm or three or fewer nodules each ≤3 cm) HCC (Milan criteria) and a likely waiting time
of longer than 6 months, locoregional therapy may be appropriate. However no one particular
type of treatment was found superior although pathologically RFA was found to cause more
tumour necrosis [133]. They also recommended that patients found to have progressed beyond
criteria acceptable for listing for liver transplantation should be placed on hold and considered
for downstaging, if this was not appropriate/not effective, they should be removed from the
waiting list. Liver resection before transplantation in patients with well preserved liver
function, and newer strategies such as a combination of TACE with RFA and use of 90-yttrium
radioembolisation or targeted therapies, have shown some benefits in preliminary studies.
Two well-documented cohort  studies  -  Rochester  (54  patients)  [134]  and Innsbruck (116
patients) [135] have confirmed that TACE allows long waiting times [median 211 days (range
28-1099 days) in the Rochester study; median 274 days (range 36-1037 days) in the Inns‐
bruck study] with relatively low total dropout rates (9% and 14%, respectively). Recurrenc‐
es were rare in both studies and were not higher than what would be expected for T2 patients.
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However a multicenter case-control study compared matched patients with TACE (100) and
without TACE (100) and the survival rates 5 years after OLT were similar (59.3% versus 59.4%)
[136]. Nevertheless, there were fewer recurrences in the TACE group (13 versus 23) but more
non–tumour-related  deaths  (15  patients  versus  7  patients).  Therefore  TACE  may  allow
patients to wait longer than would otherwise be possible, and is not associated with more
recurrences (which may in fact be less frequent). If the option of TACE is chosen, it should be
pursued (if needed with multiple treatments) until the best possible effect on tumour necrosis
is obtained [133].
RFA was not at first sight an appealing treatment in pretransplant patients because of the risk
of local spread, and there were early reports of RFA in which seeding was frequent. Experience
with the technique and a well-conducted cohort study have shown that seeding and recurrence
are rare when patients and contraindications are selected carefully (i.e., subcapsular tumours
and direct nodule puncture) [137]. Other confirmatory studies have shown that the technique
can be used safely in pretransplant patients and that the percutaneous route is as safe as the
laparoscopic approach and less cumbersome [138], [139]. In pathological studies, the results
for RFA appear to be superior to those for TACE [140] [141] and RFA appears to be associated
with less tumour progression [142]. Therefore RFA appears to be safe and can be used as a
bridging strategy if this is indicated. Its ability to reduce dropout rates and its effects on post-
transplant results need to be proven in a prospective, comparative study. In some anatomical
situations – subcapsular lesions and very large lesions (more than 5-6 cm in diameter) optimal
treatment is difficult to achieve with RFA, however this can be overcome with use of probes
which can cause larger burns and those designed for use on the surface of the liver.
Although resection appears to be safe before transplantation (in terms of operative results and
long- term outcomes) and to have a place in decision analysis when the waiting time is longer
than 1 year, resection is very rarely used at the moment as a bridging strategy. This is further
discussed in the salvage transplantation section.
Radioembolization with yttrium-90 represents 5% to 10% of bridging LRT procedures in the
OPTN registry, but data on its impact are scanty. In a study that reported the correlation
between radiological and pathological findings in patients with HCC who underwent
radioembolization with yttrium-90 microspheres before transplantation, all target lesions
demonstrated some degree of histological necrosis, and 23 of 38 (61%) showed complete
pathological necrosis [143]. A recent study retrospectively analyzed transarterial radioembo‐
lization (TARE) and TACE in similar patients (122 and 123, respectively); 44 TARE patients
and 46 TACE patients were at stage T2 [144]. Although there was no survival benefit for TARE,
the time to disease progression and the AFP responses were significantly more favourable with
TARE, and this suggests that this treatment could be a promising modality before LT but
current data are too scanty to recommend the use of TARE for this, but this technique may be
an appropriate one to use and should be the object of further investigation.
Conformal radiotherapy (CRT) is known as a feasible and efficient therapeutic option for HCC
patients who are ineligible for a curative treatment (i.e., surgical resection or transplantation).
However, minimal data exists for the use of CRT as a bridging option for patients on the waiting
list and although CRT may be a safe and potent local bridging therapy for patients with
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advanced HCC who are on the waiting list for LT [145]. Further studies are warranted to
compare the effectiveness of CRT and other local therapeutic options in this setting.
It is important to emphasize that proof that bridging treatments does not result in more
recurrences and worse outcomes after transplantation is not yet available (the above quoted
studies may have a strong selection bias in the allocation of patients to treatment and no-
treatment arms). Therefore a RCT with a no-treatment arm is the suggestion from a recent
consensus conference [133] but the ethical and logistical problems in implementing such a trial
can be substantial.
15. Role of LDLT
Living-donor liver transplantation (LDLT) using the right or left hemiliver of a healthy donor
is the best therapeutic strategy for liver transplantation in some countries, especially in Asia,
because of limited availability of deceased-donor organs. LDLT has also been used in other
countries with well established programmes for organ donation from brain dead or non-heart-
beating donors for organ shortage, long waiting times associated with deaths on the waiting
list, drop-out due to medical reasons, or progression of tumours beyond acceptable criteria.
The main issue in LDLT is donor safety, because of the risk of complications or death, even if
small. The concept of double equipoise was proposed to describe the balance between the
recipient’s survival benefit with LDLT and the risk of a complication or death of a healthy
donor [146]. The physicians might discuss probable risks and benefits with their patients and
meet the test of equipoise.
Six studies compared deceased-donor liver transplantation (DDLT) and LDLT for HCC,
including a report from a multicentre US consortium of LDLT centres [147] [148] [149] [150]-
[152]. No convincing difference in outcome could be identified according to type of graft,
although a higher risk of recurrence was noted in fast-tracked patients, since a short delay
between diagnosis and liver transplantation might not allow enough time for the biological
behaviour of the tumour to manifest. Therefore the recent consensus conference [103] sug‐
gested a period of observation (e.g., 3 months) when offering LDLT in recipients with HCC
although it is not included in their recommendations. They did recommend that LDLT is
acceptable for HCC patients who have an expected 5-year survival similar to comparably
staged patients receiving a deceased-donor liver. However a more recent meta-analysis of 12
studies which provided information on disease free survival on a total of n=633 LDLT and
n=1232 DDLT concluded lower disease free survival for LDLT [153]. This result could no doubt
occur due to reporting bias but the fact that the boundaries of criteria for LDLT are more relaxed
as compared to DDLT. Most centres would transplant HCC without macrovascular invasion
and absence of extra-hepatic disease in the setting of LDLT whilst the same tumour load would
not be considered for DDLT and this practice has been cautioned against [154].
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16. Post-LT management
The role of immunosuppression in HCC patients after liver transplantation is still controver‐
sial, because experimental models would have shown oncogenic properties of immunosup‐
pressive drugs. Currently, most programmes are careful to balance the inherent risks of
rejection and tumour recurrence. However, there are no RCTs that have shown that lowering
immunosuppression reduces the risk of HCC recurrence after liver transplantation. One class
of immunosuppressive drugs, the mTOR inhibitors, might be useful for patients with HCC
who receive a liver transplantation, since experimental studies have shown that this drug has
strong immunosuppressive effects with concomitant anti-neoplastic properties [155]. Uncon‐
trolled pilot trials and retrospective analyses have suggested that sirolimus, an mTOR
inhibitor, was associated with lower tumour recurrence and improved survival after liver
transplantation [156], [157], these results have not been confirmed in an RCT. At present,
therefore, the type or dose of immunosuppression therapy influencing the incidence of HCC
recurrence or its prognosis are still much debated [103].
There is also no evidence to support the use of adjuvant treatment to decrease risk of post LT
recurrence [103]. Numerous uncontrolled studies and 4 RCTs (n=213) [158]- [162] do suggest
some benefit but the variety of drugs used and the varied inclusion criteria and end-points
make interpretation difficult. Sorafenib (multitargeted tyrosine-kinase inhibitor) and Licartin
[159] (131I-radiolabelled murine monoclonal antibody that specifically binds HCC cells) show
some promise but are not recommended for adjuvant use after transplantation at present.
The main problem after liver transplantation for HCC is the risk of tumour recurrence, which
occurs in 8–20% of recipients. HCC recurrence occurs usually during the first 2 years after liver
transplantation, and is associated with a median survival of less than 1 year (IQR 7–18 months)
from the time of diagnosis [163]. The routine use of imaging and α-fetoprotein monitoring has
allowed earlier detection of recurrence, with a likelihood of cure with ablation therapies in up
to a third of cases [164]. However no particular protocol for surveillance has been proven and
individual centres like ours tailor their imaging frequency based on AFP levels.
The treatment of HCC recurrence after liver transplantation is much debated. Retransplanta‐
tion is not appropriate since during most recurrences there is often systemic dissemination of
tumour cells [165]. Locoregional therapy for HCC recurrence, including liver resection [166],
radiofrequency ablation, or TACE, has been successfully used in selected patients with limited
disease, and might be considered when technically feasible. Sorafenib has been used after liver
transplantation recurrence, sometimes in conjunction with mTOR inhibitors with success and
with limited side-effects [167].
17. Concluding statements
The best results for liver resection are obtained in patients with small solitary tumours. While
multifocal disease may not impede resection as regards technical feasibility, most of the data
Practical Management of Chronic Viral Hepatitis344
suggests that long-term survival even in the absence of portal hypertension is poor with a high
rate of disease recurrence [44]. This is the major drawback of surgical resection (as well as of
ablation) and is due to two mechanisms. The most frequent is cell dissemination prior to
treatment. This gives rise to metastatic nests and its incidence is higher in tumours exhibiting
microscopic vascular invasion and/or satellites [168]. More than 80% of the patients with this
profile will suffer recurrence within the first two years of follow-up and their prognosis is
negatively affected. The second mechanism for recurrence is related to the oncogenic capacity
of the background liver parenchyma which is diseased that can give rise to metachronous
tumours [168]. They are more prevalent after the two years of follow- up and their potential
to be successfully treated is higher as compared with early recurrence that is usually multifocal.
Since the prevalence of vascular invasion/satellites increases along with tumour size, it is clear
that the larger the tumour, the higher the risk of these and of recurrence. However, there are
some infrequent patients with large solitary HCC in whom the expansive tumour growth has
not been associated with development of additional tumour sites. Hence, if after proper staging
of a large HCC there is no proven dissemination, surgery should not be contraindicated, but
physicians and patients should be aware of the statistics showing that the likelihood of
microscopic vascular invasion (and hence, early recurrence after surgery) parallels tumour
size. Indeed, intraoperative ultrasound may disclose additional tumour sites not detected
preoperatively and abort the proposed resection. Careful evaluation of the non-tumoural liver
parenchyma to be resected and of the expected remaining volume is mandatory prior to
operation.
Interestingly, the risk of HCC recurrence after transplantation is less than after resection or
ablation even if stratifying for the same pathology risk profile. Hence, with similar survival
and less recurrence, it would appear reasonable to consider transplantation as the first option
as it would solve HCC and the underlying oncogenic liver. This consideration has to be
tempered by the fact that liver transplantation is not a simple procedure. Morbidity and death
rate in the early and intermediate follow-up period are higher than after resection surgery in
optimal candidates. Also, while recurrence of hepatitis B and alcoholic liver disease may be
prevented, the status in patients infected with hepatitis C virus is not so encouraging [169]
[170]. Effective viral eradication is not common in cirrhotics (the underlying disease in most
HCC), treatment pre and post-transplantation may have severe side effects, reinfection of the
graft is the rule and the long-term outcome is significantly impaired as compared to the other
populations. All these facts have maintained surgical resection as the first line surgical option
in patients with optimal profile as defined by solitary HCC in a liver without clinically relevant
portal hypertension. Operative risk is very low and analysis of the resected tumour will allow
the classification of the tumor as at low risk for recurrence (no vascular invasion or satellites)
or as at high risk because of adverse pathology profile [171]. If this is the case recurrence will
impair prognosis and if the patient had been transplanted the risk and survival would have
been significantly better. Based on this, the recommendation in these high-risk patients is to
propose transplantation because of high risk of recurrence and not delay the decision to the
appearance of recurrence as at that time multifocality will be the rule and transplantation will
be contraindicated. By contrast, if the resected tumour does not have an invasive phenotype,
the patient can avoid liver transplantation and the associated risks, while being under strict
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surveillance. Recurrence will likely correspond to a metachronous tumour and benefit again
of the same decision making process for treatment allocation [5].
Because of the lack of donor livers for transplantation, strict selection criteria were introduced
in order to achieve acceptable outcomes. Since the introduction of these Milan criteria in 1993,
LT for HCC has been associated with an overall 70% 5-year survival. Although the Milan
criteria have been criticised in recent years for being too restrictive, recent data has shown
them to have stood the ‘test of time’ and are as relevant today as they were 20 years ago.
Therefore any expansion of these criteria such as the UCSF or ‘Metro-ticket’ criteria must be
critically assessed.
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